Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma

Cancer

Volumn 97, Issue 5, 2003, Pages 1174-1180

  Venturini, Marco ^a   Durando, Antonio ^b   Garrone, Ornella ^c   Colozza, Maria Antonietta ^d   Contu, Antonio ^e   Stevani, Ilaria ^a   Genta, Franco ^b   Bighin, Claudia ^a   Lambiase, Antonio ^f   Del Mastro, Lucia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Ospedale S Anna   (Italy)

^c A Carle Hospital   (Italy)

^d Azienda Ospedaliera   (Italy)

^e Azienda USL 1   (Italy)

^f ROCHE MILANO RICERCHE   (Italy)

Author keywords

Advanced breast carcinoma; Capecitabine; Docetaxel; Epirubicin; Phase II

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CAPECITABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; INTESTINE NECROSIS; LACRIMATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROPATHY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0345505673     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11203     Document Type: Article

References (22)

1. Nabholtz JM, Falkson G, Campos D, et al. A Phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC [abstract 485]. Proc Am Soc Clin Oncol. 1999;18:127.
2. Chan S, Kay F, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-2354.
3. Bonneterre JM, Dieras V, Tubiana-Hulin M, et al. Epirubicin/docetaxel (ET) versus 5FU/epirubicin/cyclophosphamide (FEC) combinations as first line chemotherapy in patients with metastatic breast cancer (MBC) [abstract 27]. Breast Cancer Res Treat. 2001;69:215.
4. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with docetaxel/capecitabine combination therapy in anthracycline-pretreated patients: Phase III trial results. J Clin Oncol. 2002;20:2812-2823.
5. Blum JL, Jones SE, Buzdar AU, et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493.
6. Blum JL, Dieras V, Lo Russo P, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-1768.
7. Reichardt P, von Mickwitz G, Luck HJ, et al. Capecitabine: a new standard in metastatic breast cancer failing anthracycline- and taxane-containing chemotherapy: mature results of a large, multicenter Phase II trial [abstract 699]. Eur J Cancer. 2001;37(Suppl 6):191.
8. Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine (Xeloda®) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large Phase II study [abstract 435]. Breast Cancer Res Treat. 2001;69:285.
9. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566-575.
10. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.
11. Venturini M, Del Mastro L, Garrone O, et al. Phase I, dosefinding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol. 2002;13:546-552.
12. Venturini M, Michelotti A, Papaldo P, et al. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Ann Oncol. 2001;12:1097-1106.
13. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
14. Cardenal F, Montes A, Llort G, et al. Typhlitis associated with docetaxel treatment. J Natl Cancer Inst. 1996;88:1078-1079.
15. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17:1413-1424.
16. Sjöström J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised Phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999;35:1194-1201.
17. Airoldi M, Cattel L, Pedani F, et al. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat. 2001;70:185-195.
18. Viens P, Roche H, Kerbrat P, et al. Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am J Clin Oncol. 2001;24:328-335.
19. Mavroudis D, Alexopoulos A, Ziras N, et al. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter Phase II study. Ann Oncol. 2000;11:1249-1254.
20. Pagani O, Sessa C, Martinelli G, et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol. 1999;10:539-545.
21. Raab G, Borquez D, Harstrick A, et al. Phase I study of docetaxel in combination with epirubicin as first line chemotherapy in metastatic breast cancer [abstract 644]. Proc Am Soc Clin Oncol. 1998;17:168a.
22. Trudeau M, Pagani O. Epirubicin in combination with the taxanes. Semin Oncol. 2001;28(Suppl 12):41-50.